Dyne Therapeutics announced positive clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD). The drug showed significant dystrophin expression and functional improvements in patients, exceeding levels observed in other DMD treatments. Dyne plans to initiate registrational cohorts in the trial and provide an update on the path to registration by the end of 2024.